0001640455-21-000018.txt : 20210122
0001640455-21-000018.hdr.sgml : 20210122
20210122184016
ACCESSION NUMBER: 0001640455-21-000018
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210120
FILED AS OF DATE: 20210122
DATE AS OF CHANGE: 20210122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Trehu Elizabeth
CENTRAL INDEX KEY: 0001693456
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 21547405
MAIL ADDRESS:
STREET 1: C/O JOUNCE THERAPEUTICS, INC.
STREET 2: 1030 MASSACHUSETTS AVENUE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
wf-form4_161135880325048.xml
FORM 4
X0306
4
2021-01-20
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001693456
Trehu Elizabeth
C/O JOUNCE THERAPEUTICS, INC.
780 MEMORIAL DRIVE
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2021-01-20
4
M
0
6500
4.02
A
77835
D
Common Stock
2021-01-20
4
S
0
6500
12.01
D
71335
D
Stock Option (Right to Buy)
4.02
2021-01-20
4
M
0
6500
0
D
2025-12-08
Common Stock
6500.0
7050
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 25, 2020. The Reporting Person exercised no discretion with respect to these transactions.
Represents the weighted average share price of an aggregate total of 6,500 shares sold in the price range of $12.00 to $12.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The option shares vest and become exercisable in 16 quarterly installments from December 9, 2015.
/s/ Kim C. Drapkin, Attorney-in-Fact
2021-01-22